» Articles » PMID: 34597852

Vitamin D Deficiency After Allogeneic Hematopoietic Cell Transplantation Promotes T-cell Activation and is Inversely Associated with an EZH2-ID3 Signature

Overview
Date 2021 Oct 1
PMID 34597852
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Vitamin D promotes a shift from a proinflammatory to a more tolerogenic immune state in allogeneic hematopoietic cell transplant (HCT) recipients. The dominant mechanism responsible for this shift has not been elucidated. We took a multifaceted approach to evaluating the clinical and immunologic impact of low vitamin D levels in 53 HCT recipients. We used 28-plex flow cytometry for immunophenotyping, serum cytokine levels, T-cell cytokine production, and T-cell whole genome transcription. The median day-30 vitamin D level was 20 ng/mL, and deficiency was common in younger patients undergoing myeloablative transplantation. Low vitamin D levels were associated with a high CD8/Treg ratio, increased serum levels and T-cell production of proinflammatory cytokines, and a gene expression signature of unrestrained T-cell proliferation and epigenetic modulation through the PRC2/EZH2 complex. Immunophenotyping confirmed a strong association between high levels of vitamin D and an activated EZH2 signature, characterized by overexpression of ID3, which has a role in effector T-cell differentiation. Our findings demonstrate the critical role of vitamin D in modulating T-cell function in human GVHD and identify a previously undescribed interaction with EZH2 and ID3, which may impact effector differentiation and has implications to cell therapies and other forms of cancer immunotherapy. © 20XX American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Citing Articles

Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma.

Nath K, Tomas A, Flynn J, Fein J, Alperovich A, Anagnostou T Transplant Cell Ther. 2022; 28(11):751.e1-751.e7.

PMID: 35944603 PMC: 9637764. DOI: 10.1016/j.jtct.2022.08.001.

References
1.
Jagasia M, Arora M, Flowers M, Chao N, McCarthy P, Cutler C . Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2011; 119(1):296-307. PMC: 3251233. DOI: 10.1182/blood-2011-06-364265. View

2.
Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

3.
Murphy W, Welniak L, Taub D, Wiltrout R, Taylor P, Vallera D . Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998; 102(9):1742-8. PMC: 509122. DOI: 10.1172/JCI3906. View

4.
Reshef R, Saber W, Bolanos-Meade J, Chen G, Chen Y, Ho V . Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. J Clin Oncol. 2021; 39(17):1878-1887. PMC: 8260916. DOI: 10.1200/JCO.20.00619. View

5.
Caballero-Velazquez T, Montero I, Sanchez-Guijo F, Parody R, Saldana R, Valcarcel D . Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. Clin Cancer Res. 2016; 22(23):5673-5681. DOI: 10.1158/1078-0432.CCR-16-0238. View